β-连环蛋白表达与膀胱癌临床病理及预后关系的Meta分析

发布时间：2018-06-12 01:22

本文选题：β-连环蛋白 + 膀胱癌　；参考：《兰州大学》2017年硕士论文

【摘要】：目的:分析β-连环蛋白(β-catenin)在膀胱癌中异常表达情况,系统评价其异常表达与膀胱癌患者之间的临床、病理学特征或疾病预后的相关性,探讨β-catenin是否能够成为治疗膀胱癌的有效药理学靶点。方法:对“主题词+自由词”在中国CNKI文献总库6.0版本(1996年～2016年9月12日)、维普科技类期刊库6.5 (1989年～2016年9月12日)、中文生物医学类电子库(CBM) (1978年～2016年9月12日)、万方数据(会议、期刊、论文等)平台(1988年～2016年9月12日)、CDSR (Cochrane系统评价电子库)(2016年1期)、EMBase (1974年～2016年9月12日)、PubMed/Medline (1975年～2016年9月12日)及谷歌学术网页行网上查找,并翻阅期刊出版物行手工搜找,截止到2016年09月12日。遵照MOOSE (2000版)规范完成系统评价流程,对所纳入各个CCS (病例-对照研究)的一般信息行定性总结、分析,用Revman manager (5.3版本)工具行数据定量分析。用OR值、HR值、95% CI值等来评估结果,用Chi2检验、其P值来异质性结果,用Z检验、其P值评估偏倚。结果:最终归入13个研究记录,内容为CCS记录,包括了 862例膀胱癌患者,76例正常膀胱粘膜人群,含8篇英文文献,5篇中文文献。Meta分析结果如下述:(1)膀胱癌组中的β-catenin表达水平高于正常膀胱粘膜组(95%CI =(7.61-50.48) ; OR= 19.60; P 0.00001),差异有统计学意义。(2)肌层浸润性膀胱癌组中的β-catenin表达水平高于浅表性膀胱癌组(95%CI =(3.68-7.30);OR = 5.18; P 0.00001),差异有统计学意义。(3)高级别胱癌组中的β-catenin表达水平高于低级别膀胱癌组(95%CI= (2.89-5.71); OR = 4.06; P 0.00001),差异有统计学意义。(4) β-catenin表达与性别无显著相关(95%CI = (0.57, 1.96);OR = 1.06; P = 0.85),差异没有统计学意义。(5) β-catenin表达水平与肿瘤数目(多/单发)无显著性相关(95%CI= (0.36,1.88) ; OR = 0.82; P = 0.63),差异没有统计学意义。(6) β-catenin表达水平和膀胱癌无进展生存期(PFS)相关(95%CI= (1.22,6.14) ; HR = 2.74; P = 0.01),差异有统计学意义。结论:本论文Meta分析结果阐明,膀胱癌组β-连环蛋白表达水平高于正常膀胱粘膜组,即β-连环蛋白的高表达可能与膀胱癌发生有关。伴随着β-连环蛋白表达水平升高,膀胱癌有一个更高TNM分期和病理级别,PFS越短,但与其膀胱癌肿瘤数目、性别则无显著性相关。以上分析提示β-连环蛋白有可能预测出存在的初期癌变,或成为膀胱癌诊断的生物标志物。
[Abstract]:Objective: to analyze the abnormal expression of 尾 -catenin in bladder cancer, and to evaluate systematically the relationship between the abnormal expression and the clinical, pathological features or prognosis of bladder cancer. To investigate whether 尾-catenin can be an effective pharmacological target in the treatment of bladder cancer. Methods: the "subject word free words" in the Chinese CNKI literature library 6.0 version (1996 ~ 12 September 2016), Weip Science and Technology Journal Library 6.5 (1989 ~ 2016 12 September, Chinese Biomedical Electronic Library CBM) (1978 ~ 12 September 2016) Universal data Journals, papers, etc.) platform (1988-12 September 2016 / CDSR / Cochrane systematic Review Electronic Library (2016-1) / EMBase (1974-Sept. 12, 2016) and Google academic Web site search, and manual search of journal publications, As of September 12, 2016. According to the MOOSE / 2000 version), the system evaluation process was completed. The general information of each CCS (case-control study) was qualitatively summarized and analyzed, and the quantitative analysis of the data was carried out with the Revman manager version 5.3. The results were evaluated with OR value and HR value of 95% CI, with Chi2 test, P value as heterogeneity result, and with Z test with P value to evaluate bias. Results: the CCS records were included in 13 study records, including 862 bladder cancer patients and 76 normal bladder mucosa patients. The expression of 尾 -catenin in bladder cancer group was higher than that in normal bladder mucosa group (7.61-50.48); OR = 19.60; P 0.00001, the difference was statistically significant. The expression level of 尾 -catenin in the high grade cystadenocarcinoma group was higher than that in the low grade bladder cancer group (2.89-5.71; OR = 4.06; P 0.00001, P 0.00001). The expression level of 尾 -catenin in the high grade cystadenocarcinoma group was higher than that in the lower grade bladder cancer group (2.89-5.71; OR = 4.06; P 0.00001, the difference was statistically significant) 尾 -catenin expression and 尾 -catenin expression in the high grade cystadenocarcinoma group were higher than those in the lower grade bladder cancer group. There was no significant correlation between sex (95 CI = 0.57, 1.96 or = 1.06; P = 0.85, P = 0.85). There was no significant correlation between 尾 -catenin expression level and the number of tumors (multiple / single). There was no significant correlation between 95 CI = 0.36% 1.88); OR = 0.82; P = 0.63N, there was no significant difference between 尾 -catenin expression and tumor number (multiple / single); OR = 0.82; P = 0.63N, there was no significant difference in 尾 -catenin expression. The level of PFS was significantly correlated with PFS), HR = 2.74 and P = 0.01, respectively. Conclusion: the results of Meta-analysis indicate that the expression of 尾 -catenin in bladder cancer is higher than that in normal bladder mucosa, that is, the high expression of 尾 -catenin may be related to the occurrence of bladder cancer. With the increase of 尾 -catenin expression, the higher TNM stage and pathological grade of bladder cancer were, the shorter the PFS was, but there was no significant correlation between the number of bladder cancer tumors and the sex. These results suggest that 尾-catenin may be a biomarker for the diagnosis of bladder cancer.
【学位授予单位】：兰州大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.14

【参考文献】